VKTX Stock Summary and Trading Ideas (Viking Therapeutics | NASDAQ:VKTX)

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Viking Therapeutics trades on the NASDAQ stock market under the symbol VKTX.

As of April 29, 2026, VKTX stock price declined to $31.33 with 2,693,202 million shares trading.

VKTX has a beta of 1.26, meaning it tends to be more sensitive to market movements. VKTX has a correlation of 0.07 to the broad based SPY ETF.

VKTX has a market cap of $3.62 billion. This is considered a Mid Cap stock.

Last quarter Viking Therapeutics reported $0 in Revenue and -$1.38 earnings per share. This fell short of revenue expectation by $-10 million and missed earnings estimates by -$.48.

In the last 3 years, VKTX traded as high as $99.41 and as low as $8.28.

The top ETF exchange traded funds that VKTX belongs to (by Net Assets): VTI, XBI, VB, VBK, VXF.

VKTX has underperformed the market in the last year with a price return of +20.8% while the SPY ETF gained +30.5%. However, in the short term, VKTX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +3.0% vs +2.6% return in SPY. But in the last 2 weeks, VKTX shares have been beat by the market, returning -11.8% compared to an SPY return of +2.5%.

VKTX support price is $31.24 and resistance is $33.54 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VKTX shares will trade within this expected range on the day.